U.S. markets open in 3 hours 16 minutes
  • S&P Futures

    4,058.50
    -17.00 (-0.42%)
     
  • Dow Futures

    34,325.00
    -134.00 (-0.39%)
     
  • Nasdaq Futures

    11,978.25
    -32.00 (-0.27%)
     
  • Russell 2000 Futures

    1,887.20
    -7.20 (-0.38%)
     
  • Crude Oil

    81.67
    +1.69 (+2.11%)
     
  • Gold

    1,807.60
    -2.00 (-0.11%)
     
  • Silver

    23.20
    -0.05 (-0.19%)
     
  • EUR/USD

    1.0543
    +0.0012 (+0.12%)
     
  • 10-Yr Bond

    3.5060
    0.0000 (0.00%)
     
  • Vix

    20.19
    +0.35 (+1.76%)
     
  • GBP/USD

    1.2262
    -0.0034 (-0.28%)
     
  • USD/JPY

    135.3770
    +1.1060 (+0.82%)
     
  • BTC-USD

    17,304.20
    +297.15 (+1.75%)
     
  • CMC Crypto 200

    410.28
    +8.85 (+2.21%)
     
  • FTSE 100

    7,578.96
    +22.73 (+0.30%)
     
  • Nikkei 225

    27,820.40
    +42.50 (+0.15%)
     

Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes

  • Novo Nordisk A/S (NYSE: NVO) has completed posting topline results across its six Phase 3a clinical trials in the ONWARDS program of once-weekly insulin icodec in people with diabetes.

  • In ONWARDS 5 study, once-weekly insulin icodec was found to be non-inferior to once-daily basal insulin in reducing HbA1c. With that, the 52-week open-label trial met its primary endpoint at the end of the study.

  • Novo’s icodec led to a reduction of -1.68% points on HbA1c, compared to -1.31% for the once-daily control. The study comprised 1,085 insulin-naive people with type 2 diabetes. Patients on icodec also used an app to guide their dosing.

  • The news adds to ONWARDS trial readouts dating back to April.

  • In July, the company announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec.

  • Earlier this month, Novo picked up worldwide marketing rights to Zealand Pharma A/S’s (NASDAQ: ZEAL) diabetes treatment Zegalogue and inked a $1.1 billion buyout of Forma Therapeutics Holdings Inc (NASDAQ: FMTX) for its sickle cell drug.

  • Novo Nordisk expects to file for regulatory approval of once-weekly insulin icodec in the U.S., the EU, and China in 1H of 2023.

  • Price Action: NVO shares are up 2.26% at $101.88 on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.